Voyager Therapeutics (VYGR) EBT Margin (2015 - 2026)

Voyager Therapeutics has disclosed EBT Margin across 12 years of filings, most recently posting 764.16% for Q2 2026.

• In Q2 2026, EBT Margin fell 12248.0% year-over-year to 764.16%; the TTM figure through Jun 2026 stood at 311.56% (down 5983.0% YoY), while the FY2025 annual figure was 296.17%, down 21575.0% from the prior year.
• EBT Margin came in at 764.16% for Q2 2026 at Voyager Therapeutics, up from 1073.96% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 1523.23% in Q4 2022 to a low of 3239.97% in Q1 2022.
• Average EBT Margin over 5 years is 513.16%, with a median of 329.78% recorded in 2023.
• Year-over-year, EBT Margin tumbled 284652 bps in 2022 and soared 332287 bps in 2023.
• Over 5 years, EBT Margin stood at 1523.23% in 2022, then slumped by 96 bps to 63.53% in 2023, then slumped by 950 bps to 540.03% in 2024, then surged by 67 bps to 178.78% in 2025, then tumbled by 327 bps to 764.16% in 2026.
• Per Business Quant data, the three most recent EBT Margin figures were 764.16% in Q2 2026, 1073.96% in Q1 2026, and 178.78% in Q4 2025.